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Paramyxoviruses initiate infection by attaching to cell surface receptors and fusing viral and cell membranes. Viral attachment proteins,
hemagglutinin-neuraminidase (HN), hemagglutinin (HA), or glycoprotein (G), bind receptors while fusion (F) proteins direct membrane
fusion. Because paramyxovirus fusion is pH independent, virus entry occurs at host cell plasma membranes. Paramyxovirus fusion also
usually requires co-expression of both the attachment protein and the fusion (F) protein. Newcastle disease virus (NDV) has assumed
increased importance as a prototype paramyxovirus because crystal structures of both the NDV F protein and the attachment protein (HN)
have been determined. Furthermore, analysis of structure and function of both viral glycoproteins by mutation, reactivity of antibody, and
peptides have defined domains of the NDV F protein important for virus fusion. These domains include the fusion peptide, the cytoplasmic
domain, as well as heptad repeat (HR) domains. Peptides with sequences from HR domains inhibit fusion, and characterization of the
mechanism of this inhibition provides evidence for conformational changes in the F protein upon activation of fusion. Both proteolytic
cleavage of the F protein and interactions with the attachment protein are required for fusion activation in most systems. Subsequent steps in
membrane merger directed by F protein are poorly understood.D 2003 Elsevier B.V. All rights reserved.Keywords: Newcastle disease virus; F protein; Fusion; Paramyxovirus; HN protein1. Introduction
Membrane fusion directed by paramyxovirus glycopro-
teins is of particular interest, in part because of its pH
independence and because of the requirement of two sepa-
rately synthesized proteins for most members of this family.
Paramyxoviruses are negative-stranded, nonsegmented
RNA viruses. This family of viruses includes agents of
common childhood diseases such as measles, mumps, and
respiratory infections, as well as Hendra and Nipah viruses,
more serious central nervous system pathogens [1] (Table
1). Also in this family are many animal pathogens, including
Newcastle disease virus (NDV), an avian virus that is a
serious agricultural problem in many regions of the world
[2].
Paramyxovirus virions are pleomorphic, enveloped par-
ticles whose membrane is modified with two, and sometimes
three, transmembrane proteins and an M protein that lines the0005-2736/03/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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includes the genome, a 15–19-kb single-stranded RNA, and
associated proteins, the nucleocapsid protein (NP), phospho-
protein (P), and virion associated polymerase (L) [1].2. Paramyxovirus entry
Paramyxoviruses initiate infection by attaching to cell
surface receptors allowing fusion of the viral membrane
with host cell plasma membranes. All members of this
family encode two transmembrane glycoproteins that direct
these steps in virus infection, the attachment protein and the
fusion (F) protein. The virus attachment proteins are called
variously hemagglutinin-neuraminidase (HN), hemaggluti-
nin (HA), or glycoprotein (G) depending upon the virus [1]
(Table 1). The receptor for many of these viruses is a sialic
acid-containing molecule [1] while two different molecules
have been identified as measles virus receptors, CD46 and
CD150 (reviewed in Ref. [3]).
The fusion (F) protein directly mediates membrane
fusion. Perhaps the best proof of this conclusion is that
some paramyxovirus F proteins can direct this process by
Table 1
Prototype members of the family of paramyxoviruses
Virus Attachment
protein
Fusion
protein
F cleavage site
sequence
Respiroviruses HN F
Sendai virus (SV) V-P-Q-S-R
Parainfluenza virus 1 (PIV1) N-P-Q-S-R
Parainfluenza virus 3 (PIV3) P-R-T-K-R
Rubulaviruses HN F
Simian virus 5 (SV5) R-R-R-R-R
Newcastle disease virus (NDV)
Virulent R-R-Q-K/R-R
Avirulent G-R/K-Q-G-R
Mumps virus (MuV) R-R-H-K-R
Parainfluenza virus 2 (PIV2) T-R-Q-K-R
Parainfluenza virus 4 (PIV4) E-I-Q-S-R
Morbilliviruses H or HA F
Measles virus (MV) R-R-H-K-R
Canine distempter virus (CDV) R-R-H-K-R
Rinderpeste virus (RPV) R-R-H-K-R
Pneumoviruses G F
Respiratory syncytial
virus (RSV)
K-K-R-K-R-R
and R-A-R-R
Henipaviruses G F
Hendravirus (HeV) V-G-D-V-K
Nipahvirus (NiV) V-G-D-V-R
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small hydrophobic protein (SH) that has been implicated
in membrane fusion [1], however, its role is unclear. It has
been shown that the SH protein of respiratory syncytial
virus (RSV) enhances cell fusion in a transient transfec-
tion of viral envelope genes although the protein has
inhibitory effects on fusion in the context of virus infec-
tion [9,10].
In studies of paramyxovirus entry, NDV has recently
assumed increased importance as a prototype paramyxovi-
rus because crystal structures of both the NDV F protein
[11] and the attachment protein (HN) [12] have been
determined. In addition, there is a comprehensive analysis
of the structure and function of both viral glycoproteins by
mutation, reactivity of antibody, and peptides. For these
reasons, the focus below is on the structure and function of
the NDV F protein.3. Overview of paramyxovirus fusion
Membrane fusion generally proceeds in a series of
specific steps: docking of an attack membrane to a target
membrane, F protein activation, close approach of mem-
branes, membrane merger, pore formation, and pore expan-
sion [13–15]. The paramyxovirus attachment protein serves
to dock the target and attack membranes, at least initially.
Current models [16] for how the F protein directs fusion
have relied heavily upon models developed in other sys-
tems, notably HIV and influenza virus. However, as previ-
ously noted [11], several properties of the F protein,including the crystal structure, suggest that the paramyxo-
virus system may not be entirely analogous. Further com-
plicating the issue is that most F proteins expressed alone do
not mediate membrane fusion [17] but require the co-
expression of the attachment protein. It is clear that these
attachment proteins provide more than just a docking
function. While the subject of a great deal of speculation
and hypothesis [1,17], the function of the attachment protein
in fusion is one of the unsolved questions in paramyxovirus
fusion.
Paramyxovirus fusion is pH independent (reviewed in
Refs. [1,13,17]). That is, infection does not require the acid
pH of endosomes to activate fusion and infection can occur
at the host cell plasma membrane. Thus other mechanisms
must be invoked for F protein activation. As a result of the
acid independence of fusion, infected cells expressing viral
glycoproteins can fuse with adjacent cells resulting in
syncytia formation, a hallmark of paramyxovirus infection
[1]. While it has been widely assumed that virus–cell
fusion is comparable to cell–cell fusion, there is no direct
proof.
To describe paramyxovirus fusion, several questions
must be considered. First, what is the structure of the pre-
fusion or fusion competent F protein and how does this
presumably metastable structure form? Second, how is the F
protein activated and what conformational changes are
involved? Third, how does the F protein mediate the actual
membrane merger? Lastly, what is the conformation of the
post-fusion F protein?4. F protein structure
4.1. Primary structure
All paramyxovirus F proteins are type 1 glycoproteins
with an amino-terminal signal sequence, a hydrophobic
transmembrane domain (TM) located near the carboxyl
terminus, and a 25–30-amino-acid cytoplasmic domain
(CT) [18]. Typical of paramyxovirus F proteins, the
NDV F protein is a 553-amino-acid protein and is synthe-
sized as a precursor, F0 (diagramed in Fig. 1). The F0 must
be proteolytically cleaved to F1 and F2 for fusion activity
(reviewed in Ref. [1]). Like all paramyxovirus F proteins,
the NDV F protein is glycosylated. Rather surprisingly,
given the overall conservation of determinants of protein
structure in all the paramyxovirus F proteins [18], the
location and numbers of carbohydrate addition sites are
not at all conserved [18]. Thus, there are few general-
izations that can be made about the roles of carbohydrate
in this family of proteins. NDV F protein has five
carbohydrate addition sites in the presumed ectodomain,
four of which have been shown to be used by analysis of
addition site mutants [19]. Some of the side chains are
important in folding while others influence fusion activity
of the protein.
Fig. 1. Diagram of the primary sequence of the NDV F protein. Important domains in the primary sequence of the NDV F protein are diagramed. The top line
indicates amino acid position while the arrows identify polypeptides (F1 and F2) generated by proteolytic cleavage. Red domains are heptad repeat (HR)
sequences. Other domains are: ss, signal sequence; FP, fusion peptide; TM, transmembrane domain; CT, cytoplasmic tail or cytoplasmic domain.
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striking domains. The fusion peptide is a 10–15-amino-acid
sequence at the amino terminus of the F1 polypeptide
(reviewed in Refs. [1,13]). Such sequences, found in many
F proteins, are composed of hydrophobic and short-chain
amino acids and are thought to insert into the target
membranes to initiate fusion (reviewed in Ref. [13]). It
has recently been proposed that paramyxovirus F proteins
have a second fusion peptide located at an internal site in F1
[20,21] (Fig. 1).
Also present in the sequence are several heptad repeat
(HR) domains. One is located in the ectodomain adjacent to
the transmembrane region (HR2 in Fig. 1). This sequence
was first recognized due to similarities to leucine zipper
motifs in transcription factors [22]. A second, remarkably
long HR is located just carboxyl terminal to the fusion
peptide (HR1 in Fig. 1) [23]. More recently, another leucine
zipper motif (HR3) was recognized in some paramyxovirus
F proteins, including the NDV F protein [24]. This domain,
however, does not form a helix in the crystal structure of the
F protein. In addition, a fourth HR (HR4) in the F2 region of
F proteins was noted and is also present in the NDV F
protein [25,26].
4.2. Crystal structure
The recently solved crystal structure of the NDV F
protein [11] should provide a structural basis for many
biological observations about the activity of this protein.
The structure, which was determined with an uncleaved F
protein from an avirulent strain of NDV, was a homotrimer
as had been predicted by cross-linking and sucrose gra-
dients [27,28]. The three monomers are remarkably inter-
twined (Fig. 2A and B). The oligomer, which is wedge-
shaped viewed from the side (Fig. 2A), is divided into a
head, neck, and stalk domain. The head and neck regions
are composed of sequences from both the F2 and F1
polypeptides (Fig. 2C and D). The stalk region is a long,coiled-coil trimer extending from amino acid 171 to 221
and includes the carboxyl terminal region of the HR1
domain. Viewed end-on, the trimer is triangular in shape
(Fig. 2B). Two remarkable and intriguing features are a
central axial channel that extends through the head and
neck regions as well as three radial channels that intersect
the axial channel.
The structure is missing several crucial domains, which
complicate considerations of the mechanisms of fusion.
First, as is typical of crystal structures of glycoproteins,
the transmembrane and cytoplasmic domains are missing.
The crystallized protein was derived from a mutant F protein
truncated at amino acid 499 eliminating the TM and CT
domains in order to allow secretion from cells [29]. This
source of material for crystal derivation may be important
since expression of a mutant NDV F protein missing its CT
domain resulted in decreased efficiency of cleavage and
surface expression [30], suggesting that the cytoplasmic
domain may influence the conformation of the ectodomain.
Glycosylation of this truncated form of the protein was also
different than the intact protein, with a glycosylation site
used that is not used in the intact protein [19]. Another
consideration is that the protein was expressed in the
absence of the HN protein, which may affect the confor-
mation of the molecule. The conformation of the NDV F
protein on cell surfaces, as measured by binding of a peptide
antibody, changed when co-expressed with HN protein [31].
Two other important domains are missing from the
structure. One missing region, from amino acid 106 to
170, includes the cleavage site, the more amino terminal
fusion peptide, and the amino terminal half of the HR1
domain. Also missing is the region from amino acid 455 to
499, which includes the HR2 domain. Fig. 2E shows
missing domains inserted as dashed lines. Absence of these
domains may be the result of degradation of the purified
protein as well as conformational disorder [11]. These
missing domains complicate consideration of the structure
of the pre- and post-fusion conformations of the protein as
Fig. 2. Crystal structure of the NDV F protein. The structures shown are generated using coordinates deposited in protein data base [11] and presented using
Protein Explorer (University of Massachusetts). A. Side view of a space filling model of the F protein trimer with each monomer colored differently; red
corresponds to carbohydrate B. End view of a space filling model of the F protein trimer with each monomer colored differently; C. Backbone presentation of
the F trimer with each monomer colored to key location within the primary sequence. Blue corresponds to amino terminal sequences (F2 domain). Colors
progress from green to yellow to red, which colors the most carboxyl terminal regions. D. Backbone presentation of a monomer as it rests in the trimer. Colors
are the same as in C. E. Backbone presentation of a monomer with missing domains as dashed lines in black. Location of missing domains, FP, cleavage site,
HR1, and HR2 are indicated.
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fusion. Importantly, the disposition of the HR1 and HR2
domains before and after cleavage is also unknown. Fur-
thermore, the orientation of the trimer with respect to
membranes is not clear although Chen et al. [11] suggested
that the head or wide end of the oligomer is facing away
from viral membranes based on the location of antibody
neutralization escape mutations.
4.3. Alternate forms of the F protein
Analyses of the primary sequence and the crystal struc-
ture of the F protein are entirely consistent with the
classification of this protein as a type 1 glycoprotein, a
protein anchored in membranes with the amino terminus in
the ectodomain. However, analysis of synthesis of the NDV
F protein in a cell-free protein synthesizing system contain-
ing membranes led to the surprising observation that the
products of the reaction contained, in nearly equimolar
amounts, two different topological forms of the protein with
respect to membranes [32]. One form was associated with
membranes typical of a type 1 glycoprotein. A second form
was partially translocated. In addition, the carboxyl terminus
appeared to be translocated. We have also reported evidence
that this second form of the F protein exists in infected cells.
While the functional significance of this second form of the
NDV F protein is unclear, these observations raise thepossibility that the structural correlates of NDV F protein
function are incompletely understood. There are examples
of other viral glycoproteins that assume alternate topologies
with respect to membranes. The hepatitis B virus L protein
[33], the hepatitis C virus E2 protein [34], and the trans-
missible gastroenteritis M protein [35] are all reported in
at least two different topological forms with different
functions.5. Functional analysis of F protein domains
Most of the domains missing in the crystal structure have
been shown to be very important in the fusion activity of the
protein by mutational analysis and the analysis of the
structure and function of peptides with sequences from
those domains. Most significant of these domains are the
cleavage site, the fusion peptide, the cytoplasmic domain,
and two of the HR domains.
5.1. Cleavage site
A classic property of many viral F proteins, including
paramyxovirus F proteins, is the requirement of proteolytic
cleavage for fusion activity [36,37]. Cleavage of paramyxo-
virus F proteins results in disulfide-linked F2 and F1 poly-
peptides derived from the amino-terminal and carboxyl-
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cleavage depends upon the sequence at the cleavage site
(reviewed in Ref. [1]). Some F proteins have a furin
recognition site (R-X-K/R-R) and are, therefore, cleaved
in the trans-Golgi membranes. In this case, the majority of F
proteins delivered to the plasma membrane are potentially
active F proteins. Other F proteins have single basic residues
at the cleavage site and are delivered to the plasma mem-
brane in an inactive, uncleaved form. In order to direct
membrane fusion, these F proteins must be cleaved by an
extracellular host cell enzyme, usually found exclusively in
the respiratory tract. Thus, infections by paramyxoviruses
encoding F proteins without a furin sequence are usually
limited to the respiratory tract. The cleavage site sequences
of F proteins of different paramyxoviruses are shown in
Table 1.
In contrast to other paramyxovirus systems, there exist
numerous different strains of NDV, some of which encode F
proteins with a furin recognition site at the cleavage site and
some of which encode F proteins without this site [2]. The
presence or absence of the furin recognition site in the F
proteins is correlated with the virulence of the strain of virus
[38]. Virulent strains, which can result in systemic infec-
tions, encode F proteins with a furin site, while avirulent
strains, which result largely in respiratory tract infections,
do not have a furin recognition site (reviewed in Refs. [1,2]).
That both types of NDV exist in nature indicates that the
cleavage of the F protein is not related to successful delivery
of the protein to plasma membranes. Indeed, mutations of
the furin recognition cleavage site in an F protein from a
virulent strain can result in a transport-competent but
uncleaved F protein and the fusion activity can be activated
by addition of exogenous trypsin [39].
Cleavage of the F protein is also affected in undefined
ways by other regions of the molecule. For example,
mutation at amino acid 154 in the HR1 domain inhibited
cleavage of the molecule [40,41]. Similarly, as noted above,
deletion of the CT domain of the protein inhibited cleavage
[30]. These changes must affect the conformation of the
protein such that the furin site is inaccessible.
Recently it has been shown that the RSV F protein must
be cleaved in two places for fusion activity, one at the F1–F2
junction and the other within F2. This surprising finding
suggests that the RSV F protein may have structural differ-
ences from other paramyxovirus F proteins [42,43]. Indeed
the RSV F2 has an unusually long sequence between the two
cleavage sites, a sequence not present in other F proteins
[44]. Perhaps this region of the RSV F2 protein must be
excised for fusion activity.
5.2. Fusion peptides
Extensive studies of fusion peptides in many viral
systems have suggested that this domain inserts into mem-
branes disordering the bilayer in preparation for membrane
merger (reviewed in Refs. [13,15]). The amino terminalsequence of the F1 polypeptides of all paramyxovirus F
protein is remarkably similar and led to its identification as a
fusion peptide. Analysis of conservative and nonconserva-
tive point mutations in the SV5 F [45] and the NDV F
proteins [40,41] has shown that this sequence is important
for fusion activity. All mutations in the NDV F protein
fusion peptide inhibited fusion as assayed by syncytia
formation, content mixing, and hemifusion. Surprisingly,
some of the same mutations in the SV5 F protein fusion
peptide actually enhanced fusion. The reasons for these
different results are unclear and point to the differences in
these two F proteins.
Recently, Shai and coworkers have shown that another
sequence, present in both Sendai and measles virus F
proteins, has properties of a fusion peptide based on the
analysis of short peptides with sequences from this domain
[20,21]. This sequence is at the carboxyl terminus of the
HR1 domain and is located at an internal site in the head
domain of the crystal structure of F protein. This location
suggests that it would become accessible to membranes only
upon opening of the trimer head domain. It will be impor-
tant to determine if mutations in this sequence in the intact
protein can negatively affect fusion in ways similar to
mutations in the more amino-terminal fusion peptide.
5.3. HR domains
The central role of HR1 and HR2 domains in paramyxo-
virus fusion is indicated from analysis of mutant F proteins
and, most importantly, by the structure and function of
peptides with sequences of these two domains. There has
been much less analysis of the two other HR domains, but
available evidence does suggest that they also have a role in
the folding of the pre-fusion F protein and the fusion activity
of the protein.
5.3.1. HR1 and HR2 domains
The NDV HR2 domain has leucine or isoleucine residues
at ‘‘a’’ positions in four HRs. Mutation of these ‘‘a’’ position
residues inhibited fusion, providing evidence for the impor-
tance of the domain in fusion. Two or more of these ‘‘a’’
residues must be changed to affect fusion if the changes are
leucine to alanine. However, single, more nonconservative
changes in the middle of the HR inhibited fusion [28,46].
Similar results were reported for other paramyxovirus F
proteins [47]. Alterations at other positions within the
heptads had no effect on fusion [28,46]. In addition, no
mutation significantly affected intracellular transport and
surface expression, indicating that this domain does not play
a direct role in formation of the pre-fusion F protein.
Results of mutational analysis of the HR1 domain of
NDV [40,41] are less straightforward but, in sum, indicate
that the region is important in fusion as well as initial
folding of the protein. First, the HR1 domain seems to be
divided into at least two regions. While analysis is limited,
all mutations in the region carboxyl terminal to amino acid
Fig. 3. Cartoon representation of HR1–HR2 complex. Panel A shows
representation of the side view of the peptide complex. Three HR1 peptides
(blue) form a central trimer and three HR2 (red) polypeptides bind in the
grooves of the trimer. The position of the fusion peptides (black triple line)
and the TM domains (green) with respect to the peptide complex as it
would exist in the intact protein are diagramed. The sequences in between
the HR1 and HR2 domains are represented by black lines. Panel B
represents an end view of the HR1–HR2 peptide complex with the
orientation of the hydrophobic side (‘‘a’’ and ‘‘d’’ residues) of each HR
helix shown.
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In contrast, some mutations amino terminal to this position
did not inhibit surface expression. The crystal structure also
suggested the presence of two domains [11]. Residues
carboxyl terminal to position 171 form a coiled-coil trimer
while the more amino terminal residues were not visible in
the structure (Fig. 2E). Likely the coiled-coil trimer visible
in the crystal structure from amino acid 171 to 220 must
form during the folding of the molecule. The amino-termi-
nal end of the HR1 domain may be conformationally
flexible and more directly related to fusion and the confor-
mational changes in the molecule upon activation of fusion.
Many mutations in the amino terminal region of the HR1
domain (approximately amino acids 130–170) also inhibited
initial protein folding. Indeed, all mutations in the ‘‘a’’
position of the HRs inhibited surface expression of the
protein, indicating that this side of the helix plays some role
in initial folding. However, most mutations in this region in
the ‘‘d’’ position in the HRs did not affect initial folding but
did block fusion, indicating that the region is involved in
fusion activity of the protein. Mutations nearer the amino
terminus of the domain inhibited fusion more completely
than mutations further along the domain [41].
Motivated by reports that peptides with sequences from
HR domains of the HIV gp41 inhibited fusion [48–50],
several laboratories characterized the effects of paramyxo-
virus HR2 peptides on fusion and found that these peptides
also inhibited fusion [26,51–54]. In addition, peptides with
sequences from the HR1 domain inhibited fusion in several
systems [26,54,55]. Key to understanding the role of the
HR domains in fusion was the finding that peptides from
the HR1 and HR2 domains can form a complex. This
complex has been demonstrated functionally in the NDV
system. Two different laboratories have shown that mix-
tures of HR1 and HR2 peptides no longer inhibited fusion,
suggesting the formation of a complex between the pep-
tides which eliminated the fusion activities of each of the
peptides [55,56]. In contrast, mixtures of HR1 and HR2
peptides with sequences from the SV5 F protein still
inhibited fusion [54]. Complexes between these two SV5
peptides as well as complexes of HR1 and HR2 peptides
with sequences from the RSV HR domains were demon-
strated on polyacrylamide gels, and the structures of the
peptide complexes were solved by X-ray crystallography
[16,54,57]. These complexes form a six-stranded structure
with an interior core trimer of HR1 peptides and associated
HR2 peptides bound in the grooves of the trimer in an anti-
parallel fashion (Fig. 3).
These findings, coupled with analogous studies of HIV
gp41 and influenza virus HA, led to the hypothesis [16,57]
that paramyxovirus F proteins are folded such that the HR
domains are not complexed. Upon activation of fusion, the
protein undergoes a cascade of conformational changes that
result in insertion of the fusion peptide into target mem-
branes followed by complexing of the HR1 and HR2
domains. Because of the location of the HR domains inthe F protein sequence and the anti-parallel nature of the
HR1–HR2 interactions, formation of this complex would
bring the TM domain and the fusion peptide in close
proximity. This close proximity would result in the close
approach of the target membrane and the attack membrane
(Fig. 3A). It is logical, therefore, that peptides with sequen-
ces from either of these domains inhibit fusion by binding to
the other HR domain within the intact protein, interfering
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Given the structure of the peptide complex as well as
implications of the F protein crystal structure, it seems
possible that HR1 peptides could also inhibit by binding
to HR1 domains prior to the formation of the amino-
terminal region of the HR1 core trimer.
The structure of the complex also provides a rational
explanation of the phenotype of some of the HR mutants.
The hydrophobic ‘‘a’’ position residues in the predicted
HR2 helix form the surface that interacts with the HR1 core
trimer (Fig. 3B). Introduction of charged residues along this
hydrophobic face should interfere with the interaction of
HR1 and HR2 and block initial stages in membrane fusion.
More conservative changes should have less effect on
complex formation and, therefore, fusion. Indeed, this was
the result as described above [28,46]. It is also possible that
these mutations interfere with HN protein interactions.
Mutations in the ‘‘d’’ position of HR1 may affect fusion
activity of the protein by destabilizing the core HR1 trimer
or by interfering with HR2 interactions (Fig. 3B).
5.3.2. HR3 domain
A second leucine zipper-like domain present in F1 of
many paramyxovirus F protein sequences (HR3) was iden-
tified by Ghosh and Shai [58] (Fig. 1). Peptides with
sequences from this region of the Sendai F protein inhibited
fusion although similar studies in SV5 system reported no
effects of peptides on fusion mediated by the SV5 F protein
[59]. Mutational analysis of this domain in the NDV F
protein indicated that the domain was important in the
folding of the molecule [7]. The NDV HR3 domain extends
to 28 amino acids with four HRs of leucine residues.
Mutation of two of the four leucine residues resulted in
misfolded proteins that were not transported to the cell
surface. One mutation resulted in a surface expressed
protein that was conformationally abnormal and defective
in fusion. Surprisingly, mutation of the fourth leucine in the
HR has no effect on the folding or surface expression of the
molecule but rather enhanced fusion in the presence of HN
protein co-expression. This mutation also eliminated the
requirement for HN protein co-expression for syncytia
formation. This residue is located at an internal position in
the globular head of the crystal structure. Chen et al. [11]
proposed that this alteration facilitates structural transitions
in the molecule important for fusion by reducing hydropho-
bic interactions with an adjacent domain.
5.3.3. HR4 domain
In the sequence of the NDV F2 protein, as well as other
paramyxovirus F proteins, is a striking HR from amino acid
81 to 102 (HR4) and, indeed, the crystal structure shows an
alpha helix from amino acid 76 to 105 [11]. Limited
mutational analysis of this region showed it to be critical
to the folding of the molecule since all mutations made have
resulted in no surface expression (unpublished observa-
tions). Recent mutational analyses of the comparable regionin the measles virus F protein have shown that mutations in
this domain affect syncytia formation [60].
5.4. Cytoplasmic domain
Mutational analyses of the NDV, SV5, PIV3, MV, and
PIV2 F protein cytoplasmic domains have been reported and
the role of this domain in fusion varies with the F protein
[30,61,62]. Deletion of the entire domain from the PIV2 F
protein and the MV F protein had no effect on surface
expression or fusion, while deletion from the PIV3 F protein
and NDV F protein interfered with their proper folding and
surface expression. Clearly, in some cases, the CT domain
influences the folding of the ectodomain of the protein.
Elimination of the carboxyl-terminal half of the NDV F
protein cytoplasmic domain resulted in a surface-expressed
protein that was defective in syncytia formation. It has been
reported that cytoplasmic domain mutations in the SV5 F
protein allow content mixing, a result that suggests that the
domain is involved in later stages of fusion related to pore
expansion [63,64].6. Conformational changes in the F protein
The model outlined above and based on the structure and
function of HR1 and HR2 inhibitory peptides predicts that
the F protein undergoes a series of conformational changes
upon activation of fusion. Indeed, by addition of these
inhibitory peptides at different stages during the onset of
fusion, indirect evidence for such conformational shifts has
been obtained. However, results obtained in two different
paramyxovirus systems, NDV and SV5, are not consistent
and may reflect differences in paramyxovirus F proteins as
well as differences in assays.
In both systems, onset of fusion was controlled by
addition of exogenous trypsin to cells expressing an
uncleaved F protein. Upon addition of trypsin and cleavage
of F0, fusion rapidly ensued. Using such a system, the NDV
HR2 peptide inhibited fusion, as assayed by syncytia
formation, if added prior to cleavage activation, but did
not inhibit if added only after a 10-min incubation with
trypsin at 25 jC [55]. Furthermore, the peptide inhibited
fusion directed by cells expressing a cleaved F protein,
suggesting that cleaved F protein delivered to the cell
surface is, at least transiently, accessible to HR2 peptide
[52]. These combined results are consistent with the idea
that both uncleaved and cleaved F proteins, in a pre-fusion
conformation, are accessible to binding of HR2 peptide. In
contrast, HR1 peptide inhibited fusion only if added prior to
F protein cleavage and not after [55].
In contrast, similar studies in the SV5 system indicated
that the SV5 F protein was accessible to peptide inhibition at
steps only after F protein cleavage [65]. These more recent
results dissected steps in F protein conformational changes
using fusion of fluorescence dye-labeled red blood cells in
T.G. Morrison / Biochimica et Biophysica Acta 1614 (2003) 73–8480order to control docking as well as subsequent steps in
fusion. Using this assay, Russell et al. [65] concluded that
both HR1 and HR2 peptides bound to their targets only after
F cleavage and after attachment of red blood cells. Further-
more, their results indicated that HR1 peptide bound to its
target at a step earlier than the HR2 peptide. They concluded
that the F protein undergoes at least three conformational
changes, one upon cleavage, one upon docking to red blood
cells opening up the site for HR1 peptide binding, and one
upon a shift to 37j, which opens the site for HR2 peptide
binding.
The reasons for these contradictory results may be due
to differences in assay systems used, the peptides used,
and, most importantly, F proteins. Not only are the proteins
from different viruses but they also differ in their require-
ments for an attachment protein. NDV F protein is abso-
lutely dependent upon HN protein co-expression for fusion
while the SV5 F protein used is not [6]. Furthermore, it has
been recently reported that the conformation of this SV5 F
protein, derived from strain W3A, is different from that of
SV5 F protein derived from strain WR, an F protein that
reassembles the NDV F protein in its requirement for HN
protein co-expression [66]. Perhaps steps leading up to
membrane merger vary somewhat with different F proteins,
or perhaps initiation of fusion begins at different points
along a sequence of conformational changes. In any event,
it is clear that paramyxovirus F proteins undergo confor-
mational changes related to the onset of fusion, changes
that are initiated upon F protein activation. Further clarifi-
cation of these changes will be important to a full under-
standing of the mechanism of F protein-directed membrane
fusion.7. Activation of F protein fusion activity
In all fusion reactions, a key step is the activation of
fusion activity in the appropriate time and place. The acid
pH of the endosome activates most viral F proteins by
triggering conformational changes in the protein required to
initiate fusion. In acid-independent fusion, mechanisms of
activation are less well defined although in some systems it
is clear that attachment of the protein to its receptor activates
the F protein [67]. Implicit in studies of peptide inhibition of
paramyxovirus fusion is the idea that upon activation, the F
protein conformation changes. So, then, how are these
conformational changes activated?
Proteolytic cleavage of paramyxovirus F proteins is
necessary and results in conformational changes in the
protein that were initially detected as an increase in hydro-
phobicity [68]. Cleavage also changes the shape of the
trimer, as visualized in electron micrographs of purified
protein, from a cone shape to a lollipop shape [29,69]. It was
proposed that the lollipop shape corresponds to the stable,
post-fusion form of the protein. Importantly, it is not clear
how, upon cleavage in the Golgi membranes, the prematureformation of the most stable, post-fusion form of the protein
is prevented.
While necessary, proteolytic cleavage of F protein is not
sufficient for fusion, at least in most paramyxovirus sys-
tems, since expression of a cleaved F protein alone usually
does not result in membrane fusion [1,17]. Rather fusion
also usually requires the co-expression of the attachment
protein, a finding that suggests that attachment is some-
how involved in F protein activation. The role of HN pro-
tein in fusion promotion is, however, a subject of some
controversy.
Initiation of membrane fusion requires some form of
docking to target membranes. Indeed, a fundamental tenant
of paramyxovirus fusion has been that binding of attach-
ment protein to receptors is necessary for fusion activation
[1,17]. This idea was based largely on the finding that
treatment of cells with neuraminidase to remove surface
sialic acid receptors blocked fusion [1,17,70–72]. Howev-
er, this conclusion is now considerably complicated by
several more recent observations. First, there is a recent
report of mutants of NDV HN protein that have little or no
demonstrable attachment activity but still efficiently pro-
mote fusion of a co-expressed wild type F protein [73].
These mutations, in the sialic acid binding site, also depress
neuraminidase activity, which could complicate assays for
attachment activity [74]. However, we have also made a
mutation in the HN protein, at a position not in the sialic
acid binding site, that also eliminates HN protein attach-
ment activity without significantly affecting neuraminidase
or fusion promotion activities (in preparation). Second,
some F proteins can mediate fusion without attachment
protein co-expression. The RSV F protein [8,9] and the
SV5, strain W3A, F protein [6] can direct fusion without an
attachment protein. As noted above, a point mutation in the
NDV F protein HR3 domain eliminates the absolute
requirement for HN protein in syncytia formation [7]. Thus,
the relationship between the attachment function of HN
protein and fusion promotion is not straightforward. In
cases where an attachment protein is not required, how
target and attack membranes are docked is unclear. Per-
haps, there is a second receptor that interacts with F
proteins. Indeed, it is reported that the RSV F protein
interacts with glycosaminoglycans [75,76] and possibly
other molecules [77]. Alternatively, the fusion peptide, by
inserting into target membranes, may serve to dock the two
membranes. How such a docking would be controlled is
not clear.
The attachment function of HN protein is clearly not
sufficient for fusion activation in most systems. Two lines
of evidence support this idea. First, there are mutations in
the NDV HN protein that eliminate fusion promotion but
not attachment [78–80]. Second, the requirement for at-
tachment proteins is virus-specific, that is, fusion requires
that the attachment protein and the F protein be from the
same virus [81]. This observation has been interpreted to
indicate a virus-specific interaction between the attachment
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several laboratories have demonstrated such a virus-specific
HN–F protein interaction by co-immunoprecipitation or by
co-capping of the proteins on cell surfaces [82–85]. Fur-
thermore, the presumed region of the HN protein that
interacts with F protein was identified as the membrane
proximal domain, amino acids 50 to 141 in the NDV HN
protein sequence, by mapping the region of the sequence
that confers virus specificity to fusion promotion [86].
Similar results have been reported in two other paramyxo-
virus systems [87,88]. Importantly, the fusion promotion
negative mutants of the NDV HN protein also map to this
region of the protein (amino acids 74 to142) (Ref. [80] and
in preparation) suggesting that these mutations affect the
HN–F protein interactions involved in fusion.
A plausible model for the role of HN protein in NDV
fusion has been suggested by Taylor and Portner and their
colleagues based on the crystal structure of the HN protein
as well as HN protein mutational analysis [12,73]. These
investigators crystallized two forms of the HN protein, one
which they proposed was a binding form and the other a
catalytic form. They proposed that there is a single sialic
acid recognition site that can switch between binding and
catalysis. The conformational switch that occurs upon
binding to sialic acid is linked to conformational changes
in the dimer interface and/or the membrane proximal
regions of the molecule that, in turn, trigger conformational
changes in the F protein to activate fusion. Furthermore,
they propose that HN mutant proteins that still promote
fusion but are attachment-negative are in the fusion-pro-
moting conformation in the absence of binding. This
hypothesis would predict that F proteins capable of fusingFig. 4. Models for the role of attachment protein in F protein activation. Model 1:
HN protein attachment to its receptor, the HN protein interacts transiently with the
conformational changes that result in the insertion of the fusion peptide into the
approach of the target and attack membranes. Model 2: The HN and F protein
attachment of the HN protein to its receptor, the HN protein switches conformation
F protein that result in insertion of fusion peptides into target membranes, format
membranes. Both models are intended to describe a general sequence of events.without HN protein expression are already in an activated
form or readily switch to that form. Indeed, using mono-
clonal antibody reactivity, Tsurudome et al. [66] have
demonstrated that the conformation of HN protein-depen-
dent and HN protein-independent F proteins of two differ-
ent strains of SV5 are different. One epitope, accessible in
the HN protein-independent F protein but not in the HN
protein-dependent F protein, was masked in the comparable
region of the crystal structure of the HN-dependent NDV F
protein.
How might a conformational switch in the HN protein
activate the F protein? Key to this question are identifica-
tion of domains of F protein that interact with HN protein,
the timing of the interactions relative to attachment, and
definition of conformational changes that F protein under-
goes upon activation, questions that remain unresolved.
Two models have been invoked (diagramed in Fig. 4).
Initially it was proposed that HN and F proteins interact
only after HN protein receptor binding and this interaction
initiates F protein conformational changes required for
fusion (model 1) [17,79]. An alternative model is that
HN and F proteins form a metastable complex prior to
HN protein attachment [83,89,90]. HN protein attachment
and switch to a catalytic form releases the F protein
stimulating the cascade of conformational changes required
for fusion (model 2). This second model describes a
mechanism that is more analogous to current understanding
of mechanisms involved in activation of HIV- and influen-
za virus-mediated membrane fusion [91]. In this second
model, it is logical to propose that interaction of the HN
protein membrane proximal domain with the F protein
blocks the release of the fusion peptide and the formationThe HN and F proteins are transported to cell surfaces independently. Upon
F protein altering its conformation. The F protein then undergoes a series of
target membrane, the formation of the HR1–HR2 complex, and the close
s form a metastable complex on cell surfaces prior to attachment. Upon
, releasing the F protein. The release activates conformational changes in the
ion of the HR1–HR2 complex, and the close approach of target and attack
There would likely be additional intermediate steps not depicted.
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in appropriate proximity [31,92]. Indeed, we have evidence
for a direct interaction between the HN protein membrane
proximal domain and the F protein HR2 domain (in
preparation). The HR2 domain was earlier suggested to
be involved in HN protein interactions by mapping F
protein domains that confer virus specificity to HN pro-
tein-promoted fusion [93].
Experimental evidence relevant to these models is
conflicting. A point mutation in HN protein is reported
to eliminate attachment as well as co-immunoprecipitation
of HN and F proteins, a result that might support model 1
[82]. However, there are other possible interpretations of
this result. There are reports of intracellular interactions of
HN and F proteins, findings that would support model 2
[83,90,94]. However, there is no evidence that these
interactions are directly related to fusion. In support of
model 2, we have reported that co-expression of HN and
F proteins alters the conformation of cell surface F protein
and this alteration can be detected prior to attachment
[31].8. Models for initiation of paramyxovirus fusion
In sum, therefore, how paramyxovirus F proteins draw
two membranes together to initiate membrane merger
remains unresolved due to lack of information about the
structure of the pre-fusion and post-fusion F proteins,Fig. 5. Conformational changes in the F protein upon activation. Two possible con
are shown on the left. The top (A) shows the F protein oriented with the wide en
protein oriented with the wide end facing away from virion membranes. The FP an
red. Upon cleavage activation and HN protein attachment the protein undergoes
possible intermediate conformations are shown in the middle of the figure althoug
into a six-stranded, coiled coil pulling the virion (black) and target (yellow) memuncertainties about F protein conformational changes in-
volved, and the mechanism of attachment protein activation
of those changes. In addition, the orientation of the pre-
fusion form of the protein with respect to membranes is
uncertain. Two possible orientations are shown in Fig. 5,
one in which the wide end of the trimer is adjacent to viral
membranes (A) and the other with the wide end facing away
from virion membranes (B). The orientation shown in B is
favored because of the location of antigenic sites on the
molecule [11]. Several different models for conformational
changes upon activation have been proposed and are well
described by Peisajovich and Shai [95]. Most models
require that the fusion peptide of the cleaved F protein be
sequestered in some way in the post-cleavage, pre-fusion
form of the protein. Indeed, Chen et al. [11] have proposed
that the fusion peptide is inserted into radial channels seen
in the structure. Upon activation, the fusion peptide inserts
into its target membrane. It has been suggested that the
globular head domain of the F protein opens up upon
activation, releasing the amino terminal fusion peptide and
exposing the more carboxyl terminal fusion peptide for
membrane insertion [20,95]. Most models propose that the
molecule then refolds such that the HR1 and HR2 domains
complex, drawing the attack and target membranes in close
proximity. How this refolding occurs is unclear and the
structure of the post-fusion protein is unknown. Peisajovich
and Shai have proposed that, upon activation, the F protein
trimer opens like an umbrella. Then the HR1 and HR2
domains zip together, rather like closing of an umbrella,formations of uncleaved F protein trimer with respect to virion membranes
d of the trimer adjacent to virion membranes. The bottom (B) shows the F
d HR1 domains are shown in blue and the HR2, TM, and CT domains are in
a series of undefined conformational changes (represented as arrows). Two
h there are other possibilities. Finally the HR1 and HR2 domains complex
branes into close proximity.
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[20,95].9. Membrane merger and pore expansion
Subsequent to close approach, membrane fusion is pro-
posed to proceed by hemi-fusion, pore formation, and pore
expansion [13]. In paramyxovirus systems, the steps fol-
lowing close approach are not well characterized. It has
been proposed that close approach and subsequent steps are
closely coupled [65] and, indeed, there are few instances
where these subsequent steps have been separated from
close approach. It has been reported that an F protein with a
GPI anchor in place of the TM domain and CT domain can
mediate hemi-fusion but not pore formation [96]. This
report suggests a role for either the TM or CT domains in
pore formation. In addition, mutant NDV F proteins with
nonconservative changes of amino acids at the HR2–TM
interface also direct hemi-fusion but not pore formation
[46]. As yet, there are no reported studies of F protein TM
domains in fusion and it will be interesting to characterize
mutations in this domain. As described above, deletions in
the SV5 F protein CT domains block syncytia formation but
not pore formation [63,64], indicating a role of this domain
in the final stages of fusion, pore expansion. The interac-
tions of this domain with underlying cell structures and the
role of such interactions in membrane fusion will be
interesting avenues for future investigations.
Most models of fusion include the idea that multiple
oligomers of F protein must be involved for successful
membrane fusion as reported for influenza virus [97,98].
However, by measuring fusion at different ratios of expres-
sion of wild type and a cleavage mutant of the NDV F
protein, the minimal functional unit was calculated to be a
trimer [39]. By determining the UV target size of Sendai
virus for hemolysis, the size of the functional unit was also
determined to be a trimer [99].10. Conclusions
While the general outlines of mechanisms involved in
paramyxovirus fusion are emerging, there are numerous
issues that remain to be clarified. Future studies of para-
myxovirus fusion will need to focus on several questions.
Prior to fusion, what is the conformation of the HR1 and
HR2 domains in the uncleaved and cleaved F protein and
how does co-expression of the attachment protein influence
this conformation? What domains of F protein interact with
activating attachment proteins? When does the F protein
interact with attachment protein with respect to F protein
cleavage and HN protein attachment to receptors? Is there a
second virus receptor protein? What is the structure of the
post-fusion form of F protein? What F protein domains are
involved in actual membrane merger? What are the roles ofhost proteins including underlying cellular structures in final
stages of fusion, pore expansion, and syncytia formation?
Are the mechanisms of cell–cell fusion and cell–virus
fusion similar?References
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